[1] BATALLER L, KLEOPA K A, WU G F, et al. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes[J]. J Neurol Neurosurg Psychiatry, 2007,78(4): 381-385. [2] Pérez E, RUGGIERI V, MONGES S, et al. Acute encephalitis anti-ionotropic glutamate receptor activated N-methyl-D-aspartate (NMDAR): analysis of eleven pediatric cases in Argentina(Benito Yelin Award)[J]. Medicina (B Aires), 2013, 73(Suppl 1): 1-9. [3] GABLE M S, SHERIFF H, DALMAU J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project[J]. Clin Infect Dis, 2012,54(7): 899-904. [4] LOUGHAN A R, ALLEN A, PERNA R, et al. Anti-n-methyl-d-aspartate receptor encephalitis: a review and neuropsychological case study[J]. Clin Neuropsychol, 2016,30(1):150-163. [5] BRENTON J N, KIM J, SCHWARTZ R H. Approach to the management of pediatric-onset anti-n-methyl-d-aspartate (anti-nmda) receptor encephalitis: a case series[J]. J Child Neurol, 2016,31(9):1150-1155. [6] ANDREA P MANN, ELENA GREBENCIUCOVA, RIMAS V LUKAS. Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges[J]. Ther Clin Risk Manag, 2014, 10: 517-525. [7] THAÍS ARMANGUE, MAR PETIT-PEDROL, JOSEP DALMAU. Autoimmune encephalitis in children[J]. J Child Neurol, 2012, 27(11): 1460-1469. [8] NAZIF T M, Vázquez J, HONIG L S, et al. Anti-N-methyl-d-aspartate receptor encephalitis: an emerging cause of centrally mediated sinus node dysfunction[J]. Dizon Europace, 2012, 14(8): 1188-1194. [9] FRANCESC GRAUS, MAARTEN J TITULAER, RAMANI BALU,et al. A clinical approach to diagnosis of autoimmune encephalitis[J]. Lancet Neurol, 2016, 15(4): 391-404. [10] DALMAU J,ROSENFELD M R. Autoimmune encephalitis update[J]. Neuro Oncol, 2014, 16 (6): 771-778. [11] TITULAER M J, MCCRACKEN L, GABILONDO I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[J]. Lancet Neurol, 2013,12(2):157-165. [12] BARTOLINI L, MUSCAL E. Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey[J]. J Neurol, 2017, 264(4):647-653. [13] DALE R C, BRILOT F, DUFFY L V,et al.Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease[J]. Neurology, 2014, 8;83(2):142-150. [14] TITULAER M J, MCCRACKEN L, GABILONDO I, et al.Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[J]. Lancet Neurol, 2013, 12(2): 157-165. [15] BYRNE S, WALSH C, HACOHEN Y, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2(4): e130. |